Press release
Bronchitis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
To Know in detail about the Bronchitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchitis Market Forecast
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bronchitis Market Report:
• The Bronchitis market size is anticipated to grow with a significant CAGR of 4% during the study period (2020-2034)
• In September 2024, CSA Medical, Inc. announced several presentations at the European Respiratory Society (ERS) Congress in Vienna, showcasing new clinical data supporting the use of Metered CryoSpray (MCS) with the RejuvenAir® System for treating Chronic Bronchitis. During the session titled "Cutting-edge concepts in interventional pulmonology: the future is here!", Dr. Christopher Orton, Consultant Respiratory Physician at Royal Brompton Hospital, London, presented research on the potential mechanisms behind bronchial epithelial resurfacing and remodeling using MCS for COPD patients with chronic bronchitis. The study confirmed the clinical effectiveness of Metered CryoSpray in alleviating chronic bronchitis symptoms, as well as a reduction in air trapping and signs of airway remodeling or "rejuvenation."
• In July 2024, CSA Medical finished enrolling participants in its SPRAY-CB trial (NCT03893370) for patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB). This double-blind, sham-controlled trial aims to assess the impact of the Boston-based company's RejuvenAir System on improving patient outcomes.
• The Bronchiolitis Market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) projected from 2024 to 2034. This growth in the 7MM is fueled by the launch of innovative therapies, including IVX-A12 and MK-1654, among others.
• Based on DelveInsight's epidemiology model, the total number of Bronchiolitis cases in the U.S. was around 4 million in 2023. This figure is expected to increase over the forecast period (2024-2034) due to greater awareness, enhanced screening, and advances in genetic testing.
• In 2023, of the etiology-specific Bronchiolitis cases in the U.S., approximately 2 million were caused by Respiratory Syncytial Virus (RSV), while around 1 million were attributed to Non-RSV or other causes.
• In 2023, Japan recorded 677,000 bronchiolitis cases due to Respiratory Syncytial Virus, with an additional 208,000 cases linked to other causes.
• Key Bronchitis Companies: Pfizer, Sanofi, AstraZeneca, Merck, Icosavax, AstraZeneca, Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson, Yuhan Corporation, Korea United Pharm. Inc., Hyundai Pharmaceutical Co., LTD., Ahn-Gook Pharma, Bayer, Wake Forest University, Pfizer, Sanofi, Pharmaxis, EmeraMed, Abgenix, and others
• Key Bronchitis Therapies: ABRYSVO, BEYFORTUS (nirsevimab-alip):, Clesrovimab (MK-1654), IVX-A12, HL301, AGS, N02RS1, levofloxacin, YHD001, KALOMINTM, Acebrophylline, Synatura®, Avelox (Moxifloxacin, BAY12-8039), Oral N-acetycystein (NAC), Moxifloxacin, telithromycin, TPI 1020, Emeramide, ABX-IL8, and others
• The Bronchitis epidemiology based on gender analyzed that in most of the countries, male predominance was observed
• The Bronchitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchitis pipeline products will significantly revolutionize the Bronchitis market dynamics.
Bronchitis Overview
An inflammation of the airways entering the lungs is referred to as bronchitis. The person coughs as a result of the inflamed airways (trachea and bronchi) swelling and filling with mucus. The cough may linger a few days to a few weeks. The primary causes of bronchitis can include viruses, smoking, and other irritants.
Get a Free sample for the Bronchitis Market Report:
https://www.delveinsight.com/report-store/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bronchitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Bronchitis Epidemiology Segmentation:
The Bronchitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Bronchitis
• Prevalent Cases of Bronchitis by severity
• Gender-specific Prevalence of Bronchitis
• Diagnosed Cases of Episodic and Chronic Bronchitis
Download the report to understand which factors are driving Bronchitis epidemiology trends @ Bronchitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bronchitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchitis market or expected to get launched during the study period. The analysis covers Bronchitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bronchitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Bronchitis Therapies and Key Companies
• ABRYSVO: Pfizer
• BEYFORTUS (nirsevimab-alip): Sanofi/ AstraZeneca
• Clesrovimab (MK-1654): Merck
• IVX-A12: Icosavax/ AstraZeneca
• HL301: Hanlim Pharm. Co., Ltd
• AGS: Ahn-Gook Pharmaceuticals Co.,Ltd
• N02RS1: PharmaKing
• levofloxacin: Johnson & Johnson
• YHD001: Yuhan Corporation
• KALOMINTM: Korea United Pharm. Inc.
• Acebrophylline: Hyundai Pharmaceutical Co., LTD.
• Synatura®: Ahn-Gook Pharma
• Avelox (Moxifloxacin, BAY12-8039): Bayer
• Oral N-acetycystein (NAC): Wake Forest University
• Moxifloxacin: Pfizer
• telithromycin: Sanofi
• TPI 1020: Pharmaxis
• Emeramide: EmeraMed
• ABX-IL8: Abgenix
Discover more about therapies set to grab major Bronchitis market share @ Bronchitis Treatment Market
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Bronchitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bronchitis Companies: Pfizer, Sanofi, AstraZeneca, Merck, Icosavax, AstraZeneca, Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson, Yuhan Corporation, Korea United Pharm. Inc., Hyundai Pharmaceutical Co., LTD., Ahn-Gook Pharma, Bayer, Wake Forest University, Pfizer, Sanofi, Pharmaxis, EmeraMed, Abgenix, and others
• Key Bronchitis Therapies: ABRYSVO, BEYFORTUS (nirsevimab-alip):, Clesrovimab (MK-1654), IVX-A12, HL301, AGS, N02RS1, levofloxacin, YHD001, KALOMINTM, Acebrophylline, Synatura®, Avelox (Moxifloxacin, BAY12-8039), Oral N-acetycystein (NAC), Moxifloxacin, telithromycin, TPI 1020, Emeramide, ABX-IL8, and others
• Bronchitis Therapeutic Assessment: Bronchitis current marketed and Bronchitis emerging therapies
• Bronchitis Market Dynamics: Bronchitis market drivers and Bronchitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bronchitis Unmet Needs, KOL's views, Analyst's views, Bronchitis Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchitis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates here
News-ID: 4273952 • Views: …
More Releases from DelveInsight Business Research
Metastatic Triple Negative Breast Cancer Pipeline 2025: Therapies Under Investig …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Triple Negative Breast Cancer pipeline constitutes 10+ key companies continuously working towards developing 12+ Metastatic Triple Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Metastatic Triple Negative Breast Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and…
Hodgkin's Lymphoma Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hodgkin's Lymphoma pipeline constitutes 15+ key companies continuously working towards developing 20 + Hodgkin's Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hodgkin's Lymphoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hodgkin's Lymphoma Market.
The…
Netherton Syndrome Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Netherton Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ Netherton Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Netherton Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Netherton Syndrome Market.
The Netherton…
Global Hysteroscopy Devices Market Size to grow at a CAGR of 6.98% to reach USD …
According to DelveInsight's analysis, the rising prevalence of gynecological conditions including abnormal uterine bleeding, fibroids, and polyps is increasing the need for hysteroscopic assessments and interventions. This demand is further strengthened by a growing patient preference for minimally invasive procedures, which offer quicker recovery and fewer complications. Office-based hysteroscopy, in particular, is gaining traction due to its convenience and higher patient satisfaction compared to conventional surgical approaches.
DelveInsight's "Hysteroscopy Devices Market…
More Releases for Bronchitis
Rising Respiratory Disease Incidence Sparks Robust Growth In Bronchitis Treatmen …
The Bronchitis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Bronchitis Treatment Market?
The market for bronchitis treatments has seen robust expansion in the past few years, with projections showing an increase from $5.61 billion in 2024 to…
Acute Bronchitis Treatment Market: An In-Depth Analysis
The global Acute Bronchitis Treatment market was valued at approximately USD 6.3 billion in 2023 and is projected to reach around USD 9.9 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% during the forecast period.
Acute Bronchitis Treatment Market Overview
Acute bronchitis is a common respiratory condition characterized by inflammation of the bronchial tubes, leading to symptoms such as coughing and mucus production. The market's growth…
Bronchitis Treatment Market Statistical Forecast, Trade Analysis 2024 - 2031
DataM Intelligence has published a new research report on "Bronchitis Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF -…
Bronchitis Treatment Market Outlook, Insights, Size 2024-2033
The bronchitis treatment market size has grown strongly in recent years. It will grow from $5.25 billion in 2023 to $5.58 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising air pollution levels, cigarette smoking epidemic, increased respiratory infections, environmental and occupational exposures, lifestyle factors..
The bronchitis treatment market size is expected to see strong…
Acute Bronchitis Treatment Market: What are the key opportunities?
The report attempts to offer high-quality and accurate analysis of the global Acute Bronchitis Treatment Market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Acute Bronchitis Treatment market that are impacting their business. Readers can become aware of crucial opportunities available in the global Acute…
Bronchitis Market: Study Navigating the Future Growth Outlook
Global Bronchitis Market Report 2019 - Market Size, Share, Price, Trend and Forecast is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Bronchitis Market. Some of the key players profiled in the study are…
